Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This is a prospective, Open-label, comparative clinical study to asses two brilliant blue G dyes as staining agent in Vitro Retinal Surgery.
The study was designed as prospective, open label, comparative observational study. The patients over 18 years old and undergone Macular Surgery, Internal Limiting membrane removal surgery or vitreomacular traction using the two brilliant blue G dyes as staining agent in Vitro Retinal Surgery were planned to enroll the study. Two blue G dyes (Bio Blue 90 plus and ILM Blue) was randomly assigned at the subject's initial intraoperative visit, according to a computer-generated randomization schedule. During the pars plana vitrectomy, Bio Blue 90 Plus or ILM Blue dyes were injected into eye to stain ILM. Injected Dye was removed from the eye at the end of study before injecting long term tamponade. A total of 5 visits were conducted during the study. Out of them pre-operative visit was done on 1 visit, Surgery/Intraoperative visit and thereafter there were three follow-up visits. The follow- up visits were performed at 1 month, 3 months and 6 Months after the completion of Surgery. Clinical evaluation will be done recording and using staining Ability of ILM (Intra-Operatively), Visualization of Stained Membrane (Intra-Operatively),OCT parameters: (Pre-Op & Post-Op Follow-Up), FFA parameters: (Pre-Op & Post-Op Follow-Up),Fundus auto fluorescence (FAF), Multifocal ERG (Pre-Op & Post-Op Follow-Up) and Visual Field analyses (Pre-Op & Post-Op Follow-Up).
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Bio Blue 90 Plus | Patients who were underwent Macular Surgery using Bio Blue 90 Plus (Brilliant Blue G Dye; 0.25 g /l concentration in 0.5 ml BD Glass Syringe; Biotech Vision Care Pvt. Ltd., Ahmedabad, India.) | ||
| ILM Blue | Patients who were underwent Macular Surgery using ILM Blue (Brilliant Blue G Dye; 0.25 g /l concentration in 0.5 ml BD Glass Syringe; D.O.R.C. Dutch Ophthalmic Research Center (International) B.V., Zuidland, The Netherlands) |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Staining Ability of ILM | Staining of ILM is assed after dye injection with choosing Excellent/Good/ Needs to Improve by surgeon | Intra-Operatively |
| Change from Baseline to 1 Month, 3 Months and 6 Months in CMT (Central Macular Thickness) | CMT (Central Macular Thickness) in micron meters is accessed with ocular coherence tomography | Pre-Op, 1 Month, 3 Month and 6 Month |
| Change from Baseline to 1 Month, 3 Months and 6 Months in TMV ( Total Macular Volume) | TMV ( Total Macular Volume) in cubic millimeter is accessed with ocular coherence tomography | Pre-Op, 1 Month, 3 Month and 6 Month |
| Change from Baseline to 1 Month, 3 Months and 6 Months in SFCT (sub foveal choroidal thickness) | SFCT (sub foveal choroidal thickness) in cubic meter is accessed with ocular coherence tomography | Pre-Op, 1 Month, 3 Month and 6 Month |
| Change from Baseline to 1 Month, 3 Months and 6 Months in Intra-retinal cuff pathology segmentation | Intra-retinal cuff pathology segmentation in micron meter is accessed with ocular coherence tomography | Pre-Op, 1 Month, 3 Month and 6 Month |
| Change from Baseline to 1 Month, 3 Months and 6 Months in RNFL Thickness (Retinal Nerve Fiber Layer) | RNFL Thickness (Retinal Nerve Fiber Layer) in micron meter is accessed with ocular coherence tomography | Pre-Op, 1 Month, 3 Month and 6 Month |
| Change from Baseline to 1 Month, 3 Months and 6 Months in Hole diameter |
| Measure | Description | Time Frame |
|---|---|---|
| Visualization of Stained Membrane | Visualization of Membrane is assed before and after dye injection with choosing poor/good options by surgeon | Intra-Operatively |
| Visual Field Analyses | A test that measures the extent and distribution of the field of vision. A visual field test is done via automated perimetry. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Patients who were underwent Macular Surgery using study devices were included in the study
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Aysu Karatay Arsan, MD | KARTAL DR. LÜTFİ KIRDAR ŞEHİR HASTANESİ | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Kartal Dr. Lütfi Kirdar Şehir Hastanesi | Istanbul | 34865 | Turkey (Türkiye) |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D012167 | Retinal Perforations |
| D019773 | Epiretinal Membrane |
| ID | Term |
|---|---|
| D012164 | Retinal Diseases |
| D005128 | Eye Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Hole diameter in micron meter is accessed with ocular coherence tomography |
| Pre-Op, 1 Month, 3 Month and 6 Month |
| Change from Baseline to 1 Month, 3 Months and 6 Months in Optic Disc situation | Optic Disc situation is accessed with ocular coherence tomography | Pre-Op, 1 Month, 3 Month and 6 Month |
| Change from Baseline to 6 Month in Foveal perfusion characteristics | Foveal perfusion characteristics are assed with FFA(Fundus Fluorescein Angiography) | Pre-Op, 6 Month |
| Change from Baseline to 6 Month in Vascular evaluation | Vascular evaluation is assed with FFA(Fundus Fluorescein Angiography) | Pre-Op, 6 Month |
| Change from Baseline to 6 Month in Fundus auto fluorescence (FAF) | Fundus auto fluorescence (FAF) are assed with FFA(Fundus Fluorescein Angiography) | Pre-Op, 6 Month |
| Multifocal ERG | During multifocal ERG testing, the patient views a rapidly changing sequence on the monitor. The resulting electrical activity is recorded by an electrode, then amplified and analyzed. During stimulation the hexagons on the screen independently change every 13 milliseconds. They all follow the same pseudorandom sequence, with each hexagon starting at a slightly different position in this sequence. Using a cross-correlation technique, the software determines the retinal response from each of the 103 segments of the retina. | Pre-op, 1 Month, 3 Month and 6 Month |
| Overview of Adverse Events | An AE could be any unfavorable and unintended symptom, sign, disease or condition, or test abnormality whether or not considered related to the investigational product. A serious adverse event (SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent AEs (TEAE): AEs that developed/worsened during the 'on treatment period' (from first dose of study device until the end of study period). Category "AE" included participant with both serious and non-serious AE. | Through study completion, an average of 6 Months |
| Pre-op, 1 Month, 3 Month and 6 Month |
| Best Corrected Visual Acuity | Monocular visual acuity for each eye is be assessed using ETDRS charts held at 4 M. | Pre-op, 1 Month, 3 Month and 6 Month |